指南与共识特殊人群用药治疗药物监测与药物基因组学

儿科罕见病药物研发的行业现状与未来建议:IQ联盟白皮书

Pediatric Rare Diseases Development in the Pharmaceutical Industry: An International Consortium for Innovation and Quality in Pharmaceutical Development, Clinical Pharmacology Leadership Group-Pediatrics Working Group, Rare Diseases Subteam Whitepaper Examining the Current Landscape and Recommendations for the Future.
指南 / 共识 · Clin Pharmacol Ther · 2024-08-15

国际药物开发创新与质量联盟(IQ)儿科工作组罕见病小组开展基线调查,评估生物标志物与替代终点、统计方法、模型引导药物开发及公私合作四大支柱,共获得13份可评估回复。文章识别关键盲点并提供专家意见,呼吁加强平台研究、端到端定量整合及试验级安慰剂数据共享。

要点

  • 行业在儿科罕见病药物开发中需加强定量整合与跨企业学习。
  • 平台研究、端到端定量整合和试验级安慰剂数据共享是重点机会。
  • 调查识别了生物标志物、统计方法、模型引导开发及公私合作中的盲点。

核心结论

  • 呼吁业界关注平台研究、端到端定量整合及试验级安慰剂数据共享,以提升儿科罕见病药物开发效率。

研究设计与样本

  • IQ临床药理学领导组儿科工作组罕见病小组开展基线调查,评估四大定量创新支柱,获得13份可评估回复。

主要发现

  • 调查识别了生物标志物与替代终点、统计方法、模型引导药物开发及公私合作方面的关键盲点。
  • 文章提供了专家意见以弥补上述差距。

临床怎么用

  • 临床药学可关注模型引导药物开发、生物标志物与替代终点在儿科罕见病中的应用。

局限性

  • 调查仅基于13份可评估回复,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many new opportunities surround rare pediatric disease drug development, thanks to key advances in regulatory thinking and in the scientific community. As rare disease drug development brings challenges to the developers in terms of limited understanding of natural history, heterogeneity in drug response, as well as difficulty recruiting patients in pivotal trials, there has never been a greater need for quantitative integration. To understand how International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) member companies approach pediatric rare disease drug development, the rare pediatric subteam of the Clinical Pharmacology Leadership Group (CPLG) sponsored Pediatrics Working Group conducted a baseline survey to assess the four main pillars of this quantitative innovation, namely, biomarkers and surrogate end points, statistical methodologies, model-informed drug development, as well as public-private partnerships. The survey was administered by IQ and yielded 13 evaluable responders from represented companies. This article presents the key findings from this baseline identifying survey, highlighting the key blind spots, and providing insightful expert opinions to address those gaps. In summary, we call an urgent attention to the community on the opportunities to enhance integration and within-industry learnings from this analysis on aspects related to platform studies, end-to-end quantitative integration, and sharing of trial-level placebo data for better understanding of disease progression and more efficient trial designs. We collectively hope that these findings will stimulate discussion and debate around cross-industry sharing and collaboration to better delineate principles and further enhance the efficiency of rare pediatric disease drug development.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Krishna R, Sebastien B, Corriol-Rohou S, et al. Pediatric Rare Diseases Development in the Pharmaceutical Industry: An International Consortium for Innovation and Quality in Pharmaceutical Development, Clinical Pharmacology Leadership Group-Pediatrics Working Group, Rare Diseases Subteam Whitepaper Examining the Current Landscape and Recommendations for the Future. Clin Pharmacol Ther. 2024. PMID: 39145605. doi:10.1002/cpt.3422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。